Ubiquitination-Related Gene Signature, Nomogram and Immune Features for Prognostic Prediction in Patients with Head and Neck Squamous Cell Carcinoma

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2024 Jul 27

PMID 39062659

Authors

Huiwen Yang

Liuqing Zhou

Mengwen Shi

Jintao Yu

Yi Xie

Yu Sun

Affiliations

Soon will be listed here.

Abstract

The objective of this research was to create a prognostic model focused on genes related to ubiquitination (UbRGs) for evaluating their clinical significance in head and neck squamous cell carcinoma (HNSCC) patients. The transcriptome expression data of UbRGs were obtained from The Cancer Genome Atlas (TCGA) database, and weighted gene co-expression network analysis (WGCNA) was used to identify specific UbRGs within survival-related hub modules. A multi-gene signature was formulated using LASSO Cox regression analysis. Furthermore, various analyses, including time-related receiver operating characteristics (ROCs), Kaplan-Meier, Cox regression, nomogram prediction, gene set enrichment, co-expression, immune, tumor mutation burden (TMB), and drug sensitivity, were conducted. Ultimately, a prognostic signature consisting of 11 gene pairs for HNSCC was established. The Kaplan-Meier curves indicated significantly improved overall survival (OS) in the low-risk group compared to the high-risk group ( < 0.001), suggesting its potential as an independent and dependable prognostic factor. Additionally, a nomogram with AUC values of 0.744, 0.852, and 0.861 at 1-, 3-, and 5-year intervals was developed. Infiltration of M2 macrophages was higher in the high-risk group, and the TMB was notably elevated compared to the low-risk group. Several chemotherapy drugs targeting UbRGs were recommended for low-risk and high-risk patients, respectively. The prognostic signature derived from UbRGs can effectively predict prognosis and provide new personalized therapeutic targets for HNSCC.

References

Szeto G, Finley S . Integrative Approaches to Cancer Immunotherapy. Trends Cancer. 2019; 5(7):400-410. PMC: 7467854. DOI: 10.1016/j.trecan.2019.05.010. View

Kitamura N, Sento S, Yoshizawa Y, Sasabe E, Kudo Y, Yamamoto T . Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. Int J Mol Sci. 2021; 22(1). PMC: 7795499. DOI: 10.3390/ijms22010240. View

Tang T, Cheng X, Truong B, Sun L, Yang X, Wang H . Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint. Pharmacol Ther. 2020; 219:107709. PMC: 7886970. DOI: 10.1016/j.pharmthera.2020.107709. View

Wang J, Xiu J, Farrell A, Baca Y, Arai H, Battaglin F . Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. Lancet Oncol. 2023; 24(2):151-161. PMC: 10599647. DOI: 10.1016/S1470-2045(22)00783-5. View

Vucicevic D, Corradin O, Ntini E, Scacheri P, Orom U . Long ncRNA expression associates with tissue-specific enhancers. Cell Cycle. 2015; 14(2):253-60. PMC: 4614992. DOI: 10.4161/15384101.2014.977641. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Zhu G, Yang K, Xu C, Feng R, Li W, Ma J . Development of a prediction model for radiotherapy response among patients with head and neck squamous cell carcinoma based on the tumor immune microenvironment and hypoxia signature. Cancer Med. 2022; 11(23):4673-4687. PMC: 9741991. DOI: 10.1002/cam4.4791. View

Zhou L, Cheng Q, Hu Y, Tan H, Li X, Wu S . Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation. Front Oncol. 2023; 12:1030802. PMC: 9815527. DOI: 10.3389/fonc.2022.1030802. View

Gunassekaran G, Vadevoo S, Baek M, Lee B . M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021; 278:121137. DOI: 10.1016/j.biomaterials.2021.121137. View

10.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

11.

Deng L, Meng T, Chen L, Wei W, Wang P . The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020; 5(1):11. PMC: 7048745. DOI: 10.1038/s41392-020-0107-0. View

12.

Yang Y, Staudt L . Protein ubiquitination in lymphoid malignancies. Immunol Rev. 2014; 263(1):240-56. PMC: 4269229. DOI: 10.1111/imr.12247. View

13.

Bommi P, Ravindran S, Raychaudhuri P, Bagchi S . DDB2 regulates Epithelial-to-Mesenchymal Transition (EMT) in Oral/Head and Neck Squamous Cell Carcinoma. Oncotarget. 2018; 9(78):34708-34718. PMC: 6205178. DOI: 10.18632/oncotarget.26168. View

14.

Li L, Li L, Liu M, Li Y, Sun Q . Novel immune-related prognostic model and nomogram for breast cancer based on ssGSEA. Front Genet. 2023; 13:957675. PMC: 9871386. DOI: 10.3389/fgene.2022.957675. View

15.

Bai J, Zhou Y, Chen G, Zeng J, Ding J, Tan Y . Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer. Hum Pathol. 2010; 42(3):375-83. DOI: 10.1016/j.humpath.2010.09.003. View

16.

He Y, Jiang Z, Chen C, Wang X . Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res. 2018; 37(1):327. PMC: 6310928. DOI: 10.1186/s13046-018-1002-1. View

17.

Behl T, Chadha S, Sachdeva M, Kumar A, Hafeez A, Mehta V . Ubiquitination in rheumatoid arthritis. Life Sci. 2020; 261:118459. DOI: 10.1016/j.lfs.2020.118459. View

18.

van Wijk S, Fulda S, Dikic I, Heilemann M . Visualizing ubiquitination in mammalian cells. EMBO Rep. 2019; 20(2). PMC: 6362358. DOI: 10.15252/embr.201846520. View

19.

Haddad R, Seiwert T, Chow L, Gupta S, Weiss J, Gluck I . Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. J Immunother Cancer. 2022; 10(2). PMC: 8883256. DOI: 10.1136/jitc-2021-003026. View

20.

Wang F, Wang J, Wang J, Zhang L, Fu H, Li J . BCCIPβ facilitates p53 ubiquitination via binding with E6 protein in high-risk HPV positive head and neck squamous cell carcinoma. Biochem Biophys Res Commun. 2020; 529(3):685-691. DOI: 10.1016/j.bbrc.2020.05.183. View